A Phase 2b Randomized Double-blind Placebo-controlled Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of GSBR-1290 in Participants Living with Obesity (Body Mass Index = 30 kg/m2) or Overweight (Body Mass Index = 27 kg/m2) with at Least One Weight-related Comorbidity
Brief description of study
This study is evaluating a drug called GSBR-1290, which is being developed by Gasherbrum Bio, Inc. (“the Sponsor”), a biopharmaceutical company with headquarters in the United States (US), as an adjunct to diet and exercise, to improve glycemic control in adults with Type 2 diabetes (T2DM). The study drug is investigational, and is not approved by the US Federal Drug Administration (FDA) in the US, or any other regulatory agency responsible for approving medicines in any other country.
- The purpose of the GSBR-1290 investigational drug research study is:
- To test how much different dosages of the study drug affects body weight
- To test how much the study drug affects other characteristics of overweight and obesity
- To look at the effects the study drug has on subjects and on the disease (e.g., change to physical health, blood sugar levels, etc.)
- To learn about how subjects feel while taking the study drug
- To measure the amount of study drug in the blood at different times
Clinical Study Identifier: s24-01021
ClinicalTrials.gov Identifier: NCT06693843
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.